BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

GlaxoSmithKline (GSK) Enters the Small Business "Hall of Shame"


1/22/2013 7:55:50 AM

Cost cutting is an age-old practice and the pharmaceutical industry has certainly sharpened its skills in recent years. Now, though, a move by GlaxoSmithKline to increase the time by which payments are made to some of its suppliers has earned the drugmaker the distinction of being named to the ‘Hall of Shame’ by the Forum for Private Business, a group that represents small businesses in the UK. According to the organization, Glaxo (GSK) recently decided to take up to 95 days to pay suppliers instead of 60 days, a move that the Forum has called ‘bully boy behavior,’ and declared this amounts to ‘poor payment’ practices. The group also noted the drugmaker two years ago had increased payment time to 60 days. “When suppliers receive a letter like the one GSK’s suppliers are starting to receive, few have any choice but to agree to the new payment terms. There is little room for bargaining through fear they will lose the business, and no small firm wants that in the current economic climate,” the Forum says in a statement on its web site. “What makes the GSK case all the worse is the sheer size and profitability of the firm – the fourth biggest pharmaceutical company on the planet. This is not a business struggling to make its way in the world. “It is, however, a company concerned only with boosting its own profits whatever the cost to smaller firms, and has scant regard for the consequences of its actions. Most people will see this as the worst type of corporate greed imaginable. GSK can’t even argue they’ve not got past form. Only two years ago they increased supplier payment terms to 60 days, and now this. They are relentless.

Read at Pharmalot


Pharmalot
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->